Sanofi ADR (SNY) financial statements
Net income was 7.8B EUR.
Free cash flow was 7.2B EUR, and the company returned 4.8B EUR in dividends and 5.0B EUR in net buybacks.
The diluted share count fell 5% over the period (buybacks).
Income statement
Fiscal years, in EUR, from Sanofi ADR's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 10.7B EUR | 11.6B EUR | 11.4B EUR | 12.0B EUR | 12.2B EUR | 12.3B EUR | 11.9B EUR | 12.6B EUR | 13.2B EUR | 13.0B EUR |
| Gross profit | 24.0B EUR | 24.6B EUR | 24.2B EUR | 25.7B EUR | 25.2B EUR | 26.9B EUR | 28.7B EUR | 29.0B EUR | 31.1B EUR | 33.7B EUR |
| Research and development | 5.2B EUR | 5.5B EUR | 5.9B EUR | 6.0B EUR | 5.5B EUR | 5.7B EUR | 6.5B EUR | 6.5B EUR | 7.4B EUR | 7.8B EUR |
| Selling, general and admin | 9.5B EUR | 10.1B EUR | 9.9B EUR | 9.9B EUR | 9.4B EUR | 9.6B EUR | 8.7B EUR | 8.9B EUR | 9.2B EUR | 9.5B EUR |
| Operating income | 6.5B EUR | 5.8B EUR | 4.7B EUR | 3.1B EUR | 14.1B EUR | 8.1B EUR | 10.2B EUR | 7.0B EUR | 7.3B EUR | 6.3B EUR |
| Interest expense | 924M EUR | 420M EUR | 435M EUR | 440M EUR | 388M EUR | 368M EUR | 430M EUR | 1.3B EUR | 1.1B EUR | 563M EUR |
| Income tax | 1.3B EUR | 1.7B EUR | 481M EUR | 121M EUR | 1.8B EUR | 1.6B EUR | 1.9B EUR | 1.0B EUR | 1.2B EUR | 1.0B EUR |
| Net income | 4.7B EUR | 8.4B EUR | 4.3B EUR | 2.8B EUR | 12.3B EUR | 6.2B EUR | 8.4B EUR | 5.4B EUR | 5.6B EUR | 7.8B EUR |
| EPS (diluted) | 3.63 EUR | 6.64 EUR | 3.43 EUR | 2.23 EUR | 9.77 EUR | 4.95 EUR | 6.66 EUR | 4.30 EUR | 4.43 EUR | 6.37 EUR |
| Diluted shares | 1.30B | 1.27B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.23B |
Balance sheet
Fiscal years, in EUR, from Sanofi ADR's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | 10.3B EUR | 10.3B EUR | 6.9B EUR | 9.4B EUR | 13.9B EUR | 10.1B EUR | 12.7B EUR | 8.7B EUR | 7.4B EUR | 7.7B EUR |
| Receivables | 7.3B EUR | 7.2B EUR | 7.3B EUR | 7.9B EUR | 7.5B EUR | 7.6B EUR | 8.4B EUR | 8.4B EUR | 7.7B EUR | 8.4B EUR |
| Inventory | 6.9B EUR | 6.8B EUR | 7.5B EUR | 8.0B EUR | 8.4B EUR | 8.7B EUR | 9.0B EUR | 9.7B EUR | 9.4B EUR | 10.2B EUR |
| Total current assets | — | — | — | — | — | — | 34.1B EUR | 30.7B EUR | 42.6B EUR | 31.0B EUR |
| Property, plant and equipment | 10.0B EUR | 9.6B EUR | 9.7B EUR | 9.7B EUR | 9.4B EUR | 10.0B EUR | 9.9B EUR | 10.2B EUR | 10.1B EUR | 10.1B EUR |
| Goodwill | 40.3B EUR | 40.3B EUR | 44.2B EUR | 44.5B EUR | 44.4B EUR | 48.1B EUR | 49.9B EUR | 49.4B EUR | 43.4B EUR | 41.3B EUR |
| Total assets | 104.7B EUR | 99.8B EUR | 111.4B EUR | 112.6B EUR | 114.4B EUR | 120.2B EUR | 126.7B EUR | 126.5B EUR | 132.8B EUR | 126.8B EUR |
| Total current liabilities | — | — | — | — | — | — | 24.0B EUR | 24.2B EUR | 29.2B EUR | 28.3B EUR |
| Long-term debt | 16.8B EUR | 14.3B EUR | 22.0B EUR | 20.1B EUR | 19.7B EUR | 17.1B EUR | 14.9B EUR | 14.3B EUR | 11.8B EUR | 14.2B EUR |
| Total liabilities | 47.0B EUR | 41.6B EUR | 52.4B EUR | 53.4B EUR | 51.2B EUR | 51.2B EUR | 51.6B EUR | 52.1B EUR | 54.9B EUR | 55.1B EUR |
| Shareholders' equity | 57.6B EUR | 58.1B EUR | 58.9B EUR | 59.1B EUR | 63.1B EUR | 68.7B EUR | 74.8B EUR | 74.0B EUR | 77.5B EUR | 71.4B EUR |
| Net debt | 8.3B EUR | 5.3B EUR | 17.7B EUR | 15.3B EUR | 8.6B EUR | 10.2B EUR | 6.3B EUR | 7.7B EUR | 8.6B EUR | 10.9B EUR |
Cash flow
Fiscal years, in EUR, from Sanofi ADR's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 7.8B EUR | 7.4B EUR | 5.5B EUR | 7.7B EUR | 7.4B EUR | 10.5B EUR | 10.5B EUR | 10.3B EUR | 9.1B EUR | 10.8B EUR |
| Capital spending | — | — | — | 1.8B EUR | 2.1B EUR | 2.0B EUR | 2.1B EUR | 2.9B EUR | 3.2B EUR | 3.5B EUR |
| Free cash flow | — | — | — | 5.9B EUR | 5.3B EUR | 8.5B EUR | 8.4B EUR | 7.4B EUR | 5.9B EUR | 7.2B EUR |
| Stock-based compensation | 241M EUR | 263M EUR | 284M EUR | 252M EUR | 274M EUR | 244M EUR | 234M EUR | 260M EUR | 278M EUR | 313M EUR |
| Dividends paid | 3.8B EUR | 3.7B EUR | 3.8B EUR | 3.8B EUR | 3.9B EUR | 4.0B EUR | 4.2B EUR | 4.5B EUR | 4.7B EUR | 4.8B EUR |
| Share buybacks (net) | -2.9B EUR | -2.2B EUR | -1.1B EUR | -9M EUR | -822M EUR | -382M EUR | -497M EUR | -593M EUR | -302M EUR | -5.0B EUR |
| Net borrowing | 2.2B EUR | 2.4B EUR | 10.5B EUR | -70M EUR | -1.9B EUR | -2.2B EUR | -1.2B EUR | -3.6B EUR | -672M EUR | 2.9B EUR |
| Dividends per share | 2.90 EUR | 2.93 EUR | 3.01 EUR | 3.05 EUR | 3.12 EUR | 3.19 EUR | 3.32 EUR | 3.55 EUR | 3.74 EUR | 3.89 EUR |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for SNY.
Open SNY in InvestinglyQuestions
How much free cash flow does Sanofi ADR generate?
7.2B EUR in fiscal 2025 (operating cash flow minus capital spending).
From Sanofi ADR's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.